Highly efficient film-like nanocellulose-based adsorbents for the removal of loose reactive dye during textile laundering

Cellulose nanofibrils (CNFs) were surface functionalized with hexamethylenediamine (HMDA) and, further, integrated with native CNFs in various weight mass ratios to fabricate water-stable films by the solvent casting method, to be used for the removal of tri-chromatic and anionic black reactive dye with the highest bleeding effect in the very first minutes of textile laundering, and in a weight mass compared to a commercial color-catcher sheet (Delta Pronatura (DP)). The effects of CNF-HMDA content on film bath absorption, surface potential and contact angle properties, as well as dye removal kinetics from different laundering baths (A – without and B – with a detergent) in up to 140 min were studied at 20℃ versus 60℃ and using different dye concentrations (0.1–1 g/L). It was found that bath absorption is decreased significantly (up to 60%) by increasing the CNF-HMDA content in the films, as compared to using a DP color-catcher sheet, due to a morphologically denser structure with surface-positioned hydrophobic ethylene moieties of HMDA, as well as reducing electrostatic attraction groups of CNF and HMDA. Such a surface interacts kinetically faster with anionic and hydrophobic dye molecules already at 20℃, reaching up to 37–80% removal of all dye colorants in the first 20 min. In contrast, the dye removal efficacy of the DP color-catcher sheet is due to it interacting with a cationic polymer being released from the surface, which is better only for a bluish color, and at 60℃, while being between 30% and 48%, as its release is hindered and reduced by the deposition of surfactants from the detergent.

A Detailed Modular Governor-Turbine Model for Multiple-Spool Gas Turbine With Scrutiny of Bleeding Effect

Multiple-spool gas turbines are usually utilized for power supply in aircrafts, ships, and terrestrial electric utility plants. As a result, having a reliable model of them can aid with the control design process and stability analysis. Since several interconnected components are coupled both thermodynamically and through shafts, these engines cannot be modeled linearly as single shaft gas turbines. In this paper, intercomponent volume method (ICV) has been implemented for turbine modeling. A switched feedback control system incorporating bump-less transfer and antiwindup functionality is employed as governor for the engine. Validation with test results from a three spool gas turbine highlights high accuracy of turbine-governor model in various maneuvers. Results show that over-speed after load rejection is considerable due to the fact that in this arrangement, the power turbine (PT) is not coupled with the compressor which acts like a damper for single shaft gas turbines. To address this problem, bleed valves (mainly before combustion chamber) are used to arrest the over-speed by 20%. In addition, a switch is employed into the governor system to rapidly shift fuel to permissible minimum flow.

Structural and functional characterization of a specific antidote for ticagrelor

Key Points In the clinic, all oral antiplatelet medicines have a risk of bleeding complications. We present an antidote for ticagrelor that reverses its antiplatelet effect in human platelet-rich plasma and its bleeding effect in mice.

Prevalence of Anemia and Risk of Adverse Bleeding Effect of Drugs: Implication for Therapy

This study aimed to evaluate the progress in reduction of prevalence of anemia in rural Australia. It also investigates the prevalence of hypoviscosity in anaemia with a view to determine the fraction of anaemic patients at risk of drug-inducible exacerbation of anemia. Archived clinical pathology data () for the period of 1999 to 2008 were utilized. The prevalence of anemia and hypoviscosity was evaluated by working out (i) the number that fell within anemia definition as a percentage of the population and (ii) the number that fell within hypoviscosity definition as a percentage of anemic patients. The prevalence in anemic diabetes and dyslipidaemia was further determined. There was progressive reduction in anemia from 6.1% to 3.2% over the ten years period. Prevalence of anemia is statistically significantly higher in males than in females (), but protein level is lower in anemic females than in anemic males (). The results further show that up to 75% of anemic patients may benefit from NSAID or salicylates. This paper highlights differences between genders. It suggests more concerted effort in men's health and speculates a new factor to investigate in women's health.

AVE5026: A New Hemisynthetic Ultra Low Molecular Weight Heparin with Enriched Anti-Xa Activity and Enhanced Antithrombotic Activity for Management of Cancer Associated Thrombosis

AVE5026 is an ULMWH with a high anti-Xa activity associated with residual anti-IIa activity (ratio anti-Xa/IIa>30). This ratio may be favorable for use in cancer patients as it may have a higher therapeutic window. This agent is a polydisperse mixture of oligomeric heparin fragments (molecular weight 2000–3000 daltons) prepared by partial and controlled depolymerization of porcine mucosal heparin (UFH).. The anticoagulant profile of AVE5026 has been previously reported (Hoppensteadt, et al. Blood 2007). To validate the hypothesis that AVE5026 is an appropriate antithrombotic in cancer, studies were carried out to determine its antithrombotic, bleeding, tumor growth, angiogenesis and apoptosis effects in animal models. AVE5026 produced a dose-dependent antithrombotic response in the rat laser model of microvascular thrombosis (2.5 mg/kg IV, 9±1.7 laser shots; 5.0 mg/kg SC, 8±1.6 laser shots; control 3±0.8 laser shots). The relative bleeding effects of AVE5026 in a rat tail bleeding model were negligible in comparison to enoxaparin (E) and UFH (all 5 mg/kg IV; UFH >1000 sec; E 360±57 sec; AVE5026 209±29 sec; Control 215±32 seconds). Repeated administration of AVE5026 in dose ranges of 1–5 mg/kg od, SC for 14 days did not result in accumulation of the anti-Xa activity. Furthermore, in contrast to E, there was no enhancement of the hemorrhagic profile. Both E and AVE5026 inhibited tumor growth by regulating angiogenesis and apoptosis in a Lewis Lung carcinoma (14% vs. 22% decrease) rat model and in a Walker 256 carcinosarcoma model (21% vs. 30% decrease) Although comparable results to E were demonstrated in animal models of arterial thrombosis, the bleeding effect of AVE5026 were disproportionately lower. This superior safety-efficacy ratio may translate into improved antithrombotic efficacy with decreased bleeding risk, suggesting that AVE5026 may provide the optimal treatment strategy for the management of cancer associated thrombosis.